Compound: Laninamivir
SMILES: O=C(O)C=1O[C@H]([C@H](NC(=O)C)[C@H](C1)N=C(N)N)[C@H](OC)[C@H](O)CO
InChIKey: QNRRHYPPQFELSF-CNYIRLTGSA-N
Synonyms: Laninamivir, 203120-17-6, R-125489, B408IW3GL5, (2R,3R,4S)-3-acetamido-2-((1R,2R)-2,3-dihydroxy-1-methoxypropyl)-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid, DTXSID60942457, R 125489, (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-((1R,2R)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, 5-(Acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-Non-2-enonic Acid, laninamivirum, 5-(acetylamino)-4-((aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid, RefChem:152254, J05AH04, DTXCID101370859, R125489, (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid, Laninamivir (INN), LANINAMIVIR [INN], (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid, C13H22N4O7, 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid, Laninamivir [INN:JAN], Laninamivir (CS-8958), UNII-B408IW3GL5, LANI, Laninamivir (Standard), LANINAMIVIR [MI], LANINAMIVIR [MART.], LANINAMIVIR [WHO-DD], CHEMBL466246, orb1308141, SCHEMBL12284832, CHEBI:177801, GLXC-15033, EX-A4019, BDBM50009296, HY-14818R, AKOS015850995, AKOS032947260, DB12791, ML58733, AC-36457, HY-14818, MS-25321, CS-0003575, NS00069718, C21557, D09410, G13934, Q6487096, (4S ,5R,6R)-5-Acetamido-4-guanidino-6-((1R,2R)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, (4S,5R,6R)-5-Acetamido-4-guanidino-6- ((1R,2R)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic Acid, 5-Acetamido-2,6-anhydro-4-(carbamimidoylamino)-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid, 5-Acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
Theoretical properties:
molecular_formula: C13H22N4O7
molecular_weight: 346.34 g/mol
exact_mass: 346.14884905 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 6
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 7
heavy_atom_count: 24
topological_polar_surface_area: 190 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Laninamivir is a member of acetamides.
chembl: LANINAMIVIR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. It is currently in Phase III clinical trials. It is a long-acting neuraminidase inhibitor administered by inhalation.
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals  and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals  (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. It is under clinical evaluations in other countries.